Drug Information

Drug General Information
Drug ID
D01NQM
Former ID
DIB009126
Drug Name
Lasmiditan
Synonyms
COL-144; LY-573144; Migraine therapy, CoLucid
Drug Type
Small molecular drug
Indication Migraine [ICD9: 346; ICD10:G43] Phase 3 [532737], [540550]
Company
Colucid pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C19H18F3N3O2
InChI
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
InChIKey
XEDHVZKDSYZQBF-UHFFFAOYSA-N
PubChem Compound ID
11610526
PubChem Substance ID
16713395, 23720613, 76634020, 85228481, 136946411, 137147749, 141745096, 144116130, 162108817, 163372026, 163839264, 164041612, 172232432, 174489630, 178100757, 189561493, 198939474, 210275146, 210280785, 223397632, 223554889, 224226843, 226846319, 242060135, 244038842, 252493599
Target and Pathway
Target(s) 5-hydroxytryptamine 1F receptor Target Info Agonist [532737]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 532737Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014 Mar 31;10:547-52.
Ref 540550(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3928).
Ref 532737Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014 Mar 31;10:547-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.